Reassessment Dynamics of Orphan Drugs in Germany’s Benefit Assessment Process.

This analysis delves into the unique processes surrounding the reassessment of orphan drugs in Germany, highlighting the evolving benefit assessment framework and its influence on patient access, regulatory compliance, and market dynamics.

Presented at ISPOR EU 2024, Barcelona, Spain.

Please click here to download the poster. Don’t forget to subscribe to our newsletter below for the latest company updates, recently published HTA guidance, industry insights, and more!

‍